A Consortium led by HIL wins major R&D grant by European Union

The European Commission managing Horizon 2020 – the EU Framework Program for Research and Innovation – today announced its decision to fully fund a proposal by HIL and its European partners THALES (France) and INFN (Italy).

The project, with a total budget of €3.8M over two years, will be funded by the ultra-competitive Horizon 2020 FTI (Fast Track to Innovation) instrument.

With this financial support from the EU, HIL will accelerate the establishment of its new state-of-the art R&D and manufacturing facility in Jerusalem, and the world-first Alpha system to be housed in this facility; THALES will continue to develop advanced laser technologies to power HIL’s laser-based proton accelerator, and INFN will provide novel detectors to accurately characterize the proton beam generated by HIL’s accelerator.

This prestigious grant will help HIL and its partners further advance the development of innovative Proton Therapy solutions, towards commercialization in the near future.